Belgian biotechnology firm Cardio3 BioSciences has secured approval from the Italian Medicines Agency (Agenzia Italiana del Farmaco) to start its congestive heart failure cardiopoietic regenerative therapy (CHART-1) European Phase III trial ...
Tags: Cardio3 Biosciences, C-Cure Drug